The list of Rapid Uptake Products for 2020/21 is currently being updated. Support for Cladribine and PCSK9i is continuing through 20/21. Further information on support for the remaining Rapid Uptake Products will follow during August/September 2020.
- Cladribine is an oral treatment given as two treatment courses, one year apart, for treating highly active relapsing-remitting multiple sclerosis in adults.
- PCSK9 inhibitors for treatment of very high cholesterol are used together with a statin-type cholesterol-lowering medicine, or in those who are unable to take or tolerate a statin.